JP2007536933A5 - - Google Patents

Download PDF

Info

Publication number
JP2007536933A5
JP2007536933A5 JP2007513283A JP2007513283A JP2007536933A5 JP 2007536933 A5 JP2007536933 A5 JP 2007536933A5 JP 2007513283 A JP2007513283 A JP 2007513283A JP 2007513283 A JP2007513283 A JP 2007513283A JP 2007536933 A5 JP2007536933 A5 JP 2007536933A5
Authority
JP
Japan
Prior art keywords
seq
cell
antibody
pharmaceutical composition
immunoglobulin chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007513283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007536933A (ja
JP5623690B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/016357 external-priority patent/WO2005110475A2/en
Publication of JP2007536933A publication Critical patent/JP2007536933A/ja
Publication of JP2007536933A5 publication Critical patent/JP2007536933A5/ja
Application granted granted Critical
Publication of JP5623690B2 publication Critical patent/JP5623690B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007513283A 2004-05-10 2005-05-10 抗体 Expired - Lifetime JP5623690B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56989204P 2004-05-10 2004-05-10
US60/569,892 2004-05-10
PCT/US2005/016357 WO2005110475A2 (en) 2004-05-10 2005-05-10 Antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011121078A Division JP2011200247A (ja) 2004-05-10 2011-05-30 抗体

Publications (3)

Publication Number Publication Date
JP2007536933A JP2007536933A (ja) 2007-12-20
JP2007536933A5 true JP2007536933A5 (https=) 2008-06-26
JP5623690B2 JP5623690B2 (ja) 2014-11-12

Family

ID=35394680

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007513283A Expired - Lifetime JP5623690B2 (ja) 2004-05-10 2005-05-10 抗体
JP2011121078A Pending JP2011200247A (ja) 2004-05-10 2011-05-30 抗体
JP2014003463A Pending JP2014094010A (ja) 2004-05-10 2014-01-10 抗体
JP2014156064A Withdrawn JP2014223084A (ja) 2004-05-10 2014-07-31 抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011121078A Pending JP2011200247A (ja) 2004-05-10 2011-05-30 抗体
JP2014003463A Pending JP2014094010A (ja) 2004-05-10 2014-01-10 抗体
JP2014156064A Withdrawn JP2014223084A (ja) 2004-05-10 2014-07-31 抗体

Country Status (27)

Country Link
US (8) US7604800B2 (https=)
EP (3) EP1765396B1 (https=)
JP (4) JP5623690B2 (https=)
KR (1) KR101256400B1 (https=)
CN (2) CN103980361B (https=)
AR (1) AR048781A1 (https=)
AU (1) AU2005244072C1 (https=)
BR (1) BRPI0510567B8 (https=)
CA (3) CA2812040C (https=)
DK (1) DK1765396T3 (https=)
EC (1) ECSP067056A (https=)
EG (1) EG26781A (https=)
ES (3) ES2598034T3 (https=)
IL (3) IL178838A (https=)
MX (1) MXPA06012986A (https=)
MY (1) MY148646A (https=)
NO (1) NO341844B1 (https=)
NZ (3) NZ578647A (https=)
PH (1) PH12015500247A1 (https=)
PL (1) PL1765396T3 (https=)
PT (1) PT1765396E (https=)
RU (1) RU2482131C2 (https=)
SG (2) SG187443A1 (https=)
TW (2) TWI402274B (https=)
UA (1) UA100356C2 (https=)
UY (1) UY28886A1 (https=)
WO (1) WO2005110475A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
CN1985000B (zh) * 2004-05-11 2012-05-30 艾比吉诺米克斯合作公司 诱导t细胞死亡的表位
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
JP5773352B2 (ja) * 2008-10-28 2015-09-02 塩野義製薬株式会社 抗ｍｕｃ１抗体
TWI496295B (zh) * 2008-10-31 2015-08-11 Semiconductor Energy Lab 半導體裝置及其製造方法
GB0822011D0 (en) * 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
EP2473531A4 (en) * 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
CA2803937A1 (en) * 2010-06-30 2012-01-05 Mount Sinai Hospital Reagents and methods for diagnosing conditions associated with hydroxylated hif 1-a
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
MX358447B (es) * 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.
CA2850885A1 (en) 2011-10-17 2013-04-25 Westfaelische Wilhelms-Universitaet Muenster Assessment of pml risk and methods based thereon
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
TWI660972B (zh) * 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
EP3334453A4 (en) * 2015-08-13 2019-02-06 New York University ANTIBODY-BASED SPECIFIC MOLECULES AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY, FOR TAU'S SPECIFIC ASP421 EPITOP
SG11201805557SA (en) * 2016-01-08 2018-07-30 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
EP3568159A4 (en) * 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES
KR102715540B1 (ko) 2017-03-14 2024-10-08 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
KR102767692B1 (ko) 2018-07-20 2025-02-17 피에르 파브르 메디카먼트 Vista의 수용체
CA3141334A1 (en) * 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
CN118949063A (zh) * 2020-01-22 2024-11-15 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
WO2023091958A1 (en) * 2021-11-17 2023-05-25 Altrubio Inc. Methods of using anti-psgl-1 antibodies in combination with jak inhibitors to treat t-cell mediated inflammatory diseases or cancers
TW202540180A (zh) * 2023-11-17 2025-10-16 美商美國全心醫藥生技股份有限公司 抗psgl-1抗體及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5378464A (en) 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
ATE179210T1 (de) * 1992-03-17 1999-05-15 Novartis Erfind Verwalt Gmbh Gentechnologisch hergestellte antikörper
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
WO1994014836A1 (en) 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
NZ261991A (en) 1993-01-25 1998-04-27 Dana Farber Cancer Inst Inc Chimeric l and p selectin made by exchange of domains, uses thereof
CZ287295A3 (en) * 1993-05-05 1996-05-15 Cytel Corp Antibodies against p-selectin, method of detecting p-selectin, preparation processes of medicaments, pharmaceutical preparations, nucleic acids, cell lines and their use
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
EP0850243B1 (en) 1995-08-03 2003-10-08 Board Of Regents Of The University Of Oklahoma o-glycan inhibitors of selectin mediated inflammation
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
JP3248570B2 (ja) * 1997-10-09 2002-01-21 日本電気株式会社 半導体装置の製造方法
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
MXPA01004310A (es) 1998-10-30 2003-06-06 Cbr Lab Inc Inhibicion de diferenciacion de celulas t citotoxicas mediante antagonistas de ligando de p-selectina (psgl).
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
ATE321570T1 (de) * 2000-05-19 2006-04-15 Blood Res Center Verfahren zur behandlung von hämostatischen störungen durch lösliches p-selectin
CN1124928C (zh) * 2000-07-11 2003-10-22 湛江包装材料企业有限公司 光降解双向拉伸聚丙烯薄膜的制造方法
EP1325123A4 (en) * 2000-09-12 2004-07-21 Inst Genetics Llc STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CA2433225A1 (en) 2000-12-29 2002-07-11 Bio-Technology General, Inc. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US6884619B2 (en) * 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
CN1985000B (zh) 2004-05-11 2012-05-30 艾比吉诺米克斯合作公司 诱导t细胞死亡的表位
MX358447B (es) 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.

Similar Documents

Publication Publication Date Title
JP2007536933A5 (https=)
RU2487723C2 (ru) Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток
ES2917000T3 (es) Interferón-gamma mutante diana y usos del mismo
Valent et al. Immunotherapy-based targeting and elimination of leukemic stem cells in AML and CML
JP2007500132A5 (https=)
HRP20201770T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
RU2019119442A (ru) Новый коньюгат аманитина
CA2451353A1 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
JP2013541335A5 (https=)
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
EP2860189A3 (en) Human cytomegalovirus neutralising antibodies and use thereof
MA43330B1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA43328A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
JP2015508757A5 (https=)
RU2006143686A (ru) Антитела
CN112074267A (zh) 成纤维细胞结合剂及其用途
JP2010533498A5 (https=)
JP2010502207A5 (https=)
JP2006523453A5 (https=)
AR045247A1 (es) Anticuerpos humanos modificados anti-igf-1r
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
JP2012143232A5 (https=)
FI3277321T3 (fi) T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
JP2020500510A5 (https=)
JP2016509585A5 (https=)